Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer

clinical trial

Details

Instance of: clinical trial
Start time: February 2014
End time: September 2019
Country: Belgium, France, Germany, Italy, Luxembourg, Netherlands, Spain, United Kingdom
Main subject: thyroid medullary carcinoma
contributor to the creative work or subject: Worldwide Clinical Trials (United States)
maximum age: 99
minimum age: 18
number of participants: 80
short name: Caprelsa104
study type: observational study
title: European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib in RET Mutation Negative and Positive Patients With Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer

Nothing in the MetaHistoryBook collection references this item yet.